Rigel Pharmaceuticals vs Xeris Biopharma
Rigel Pharmaceuticals reported revenue of $294 million in fiscal 2025, about the same as Xeris Biopharma's $292 million in fiscal 2025. Rigel Pharmaceuticals' revenue grew 64.2% in its latest year, and Xeris Biopharma's grew 43.7%. Rigel Pharmaceuticals had an operating margin of 42.6%, against 8.5% at Xeris Biopharma.
Side by side
| Rigel Pharmaceuticals | Xeris Biopharma | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $294M | $292M |
| Revenue growth | 64.2% | 43.7% |
| Revenue growth a year, last 5 years | 22.1% | 70.3% |
| Gross margin | 93.3% | — |
| Operating margin | 42.6% | 8.5% |
| Net margin | 124.7% | 0.2% |
| Free cash flow | — | — |
| Free cash flow margin | — | — |
| Return on capital | 91.3% | 19.6% |
| Net debt to EBITDA | −0.8x | 4.2x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 6.5% | 17.7% |
| Last close | $44.46 | $16.66 |
| P/E at the last close | 2.8× | — |
| Insider trades, last 12 months | — | sold $4.7 million |
| Piotroski F-score | 7 of 9 | 7 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Rigel PharmaceuticalsXeris Biopharma
Operating margin
Percent of revenue
Rigel PharmaceuticalsXeris Biopharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Rigel PharmaceuticalsXeris Biopharma
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Rigel Pharmaceuticals and Xeris Biopharma pages.